Simulations Plus Inc. (SLP)
| Bid | 33.75 |
| Market Cap | 679.75M |
| Revenue (ttm) | 78.56M |
| Net Income (ttm) | 7.22M |
| EPS (ttm) | 0.36 |
| PE Ratio (ttm) | 93.89 |
| Forward PE | 27.32 |
| Analyst | Buy |
| Ask | 33.84 |
| Volume | 172,613 |
| Avg. Volume (20D) | 279,863 |
| Open | 34.34 |
| Previous Close | 34.35 |
| Day's Range | 32.62 - 34.34 |
| 52-Week Range | 23.01 - 51.22 |
| Beta | 1.13 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus...
Analyst Forecast
According to 7 analyst ratings, the average rating for SLP stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 47.93% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Simulations Plus: I See Promising Growth, But I'm Staying NeutralSimulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and p...
4 weeks ago · businesswire.com
Simulations Plus Reports Second Quarter Fiscal 2025 Financial ResultsRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...
